Heterologous ChAdOx1-BNT162b2 vaccination in Korean cohort induces robust immune and antibody responses that includes Omicron

Lee, Hye Kyung; Go, Jinyoung; Sung, Heungsup; Kim, Seong Who; Walter, Mary; Knabl, Ludwig; Furth, Priscilla A.; Hennighausen, Lothar; Huh, Jin Won

doi:10.1016/j.isci.2022.104473

Cited by 24 publications

(21 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interferon-mediated innate immune response serves as a biomarker and plays a critical role in the immune system to control viral replication combating SARS-CoV-2 infection. 17,45,46 Skewed IGHV usage, including the appearance of IGHV1-69, IGHV 4-34, and IGHV 3-21, was observed in the BCR repertoire of the CLL patients. Diverse IGHV usage occurs in COVID-19 patients and vaccinated individuals.…”

Section: Discussionmentioning

confidence: 99%

“…Reference cohorts were healthy individuals receiving heterologous or homologous vaccinations. 17 4; Supplementary Figures 1-2). IFN- enrichment scores for DEGs at D2 were independent of antibody response.…”

Section: Transcriptional Immune Responsementioning

confidence: 99%

“…The copyright holder for this this version posted September 21, 2022. ; https://doi.org/10.1101/2022.09.21.22280205 doi: medRxiv preprint hematological disease. 16,17 The European Medicines Agency (EMA) and the European Centre for Disease Prevention and Control (ECDC) discussed potential benefits of heterologous regimens in 2021. 18 While CLL patients who received their last treatment within 12 months preceding standard vaccination program demonstrate low response rates, vaccine response rates increase in seronegative, actively treated patients following boosting.…”

Section: Introductionmentioning

confidence: 99%

“…14,15 Heterologous vaccine schedules also enhance humoral response in individuals without hematological disease. 16,17 The European Medicines Agency (EMA) and the European Centre for Disease Prevention and Control (ECDC) discussed potential benefits of heterologous regimens in 2021. 18…”

Section: Introductionmentioning

confidence: 99%

“…Early responses to vaccination are elevated levels of interferons and other cytokines, which activate the JAK/STAT signaling pathway and induce expression of immediate and innate response genes. We have used RNA-seq of peripheral immune cells to identify the innate immune response of healthy individuals receiving the standard homologous BNT162b2 25 or a heterologous ChAdOx1/BNT162b2 17 regimen. Specific genetic pathways are differentially activated within the first two days after vaccination and more prominently in the heterologous cohort.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Comprehensive analysis of immune responses in CLL patients after heterologous COVID-19 vaccination

Lee

Hoechstetter²,

Buchner

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Patients with chronic lymphocytic leukemia (CLL) treated with B-cell pathway inhibitors and anti-CD20 antibodies exhibit low humoral response rate (RR) following SARS-CoV-2 vaccination. To investigate the relationship between the initial transcriptional response to vaccination with ensuing B and T cell immune responses, we performed a comprehensive immune transcriptome analysis flanked by antibody and T cell assays in peripheral blood prospectively collected from 15 CLL/SLL patients vaccinated with heterologous BNT162b2/ChAdOx1 with follow up at a single institution. The two-dose antibody RR was 40% increasing to 53% after booster. Patients on BTKi, venetoclax and/or anti-CD20 antibody within 12 months of vaccination responded less well than those under BTKi alone. The two-dose T cell RR was 80% increasing to 93% after booster. Transcriptome studies revealed that seven patients showed interferon-mediated signaling activation within 2 days and one at 7 days after vaccination. Increasing counts of COVID-19 specific IGHV genes correlated with B-cell reconstitution and improved humoral RR. T cell responses in CLL patients appeared after vaccination regardless of treatment status. A higher humoral RR was associated with BTKi treatment and B-cell reconstitution. Boosting was particularly effective when intrinsic immune status was improved by CLL-treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Transcriptional Immune Responsementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Comprehensive analysis of immune responses in CLL patients after heterologous COVID-19 vaccination

Lee

Hoechstetter²,

Buchner

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

Comparable CD8⁺ T‐cell responses to SARS‐CoV‐2 vaccination in single‐cell transcriptomics of recently allogeneic transplanted patients and healthy individuals

Tranter,

Frentsch,

Hütter‐Krönke

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

Despite extensive research on severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccination responses in healthy individuals, there is comparatively little known beyond antibody titers and T‐cell responses in the vulnerable cohort of patients after allogeneic hematopoietic stem cell transplantation (ASCT). In this study, we assessed the serological response and performed longitudinal multimodal analyses including T‐cell functionality and single‐cell RNA sequencing combined with T cell receptor (TCR)/B cell receptor (BCR) profiling in the context of BNT162b2 vaccination in ASCT patients. In addition, these data were compared to publicly available data sets of healthy vaccinees. Protective antibody titers were achieved in 40% of patients. We identified a distorted B‐ and T‐cell distribution, a reduced TCR diversity, and increased levels of exhaustion marker expression as possible causes for the poorer vaccine response rates in ASCT patients. Immunoglobulin heavy chain gene rearrangement after vaccination proved to be highly variable in ASCT patients. Changes in TCRα and TCRβ gene rearrangement after vaccination differed from patterns observed in healthy vaccinees. Crucially, ASCT patients elicited comparable proportions of SARS‐CoV‐2 vaccine‐induced (VI) CD8+ T‐cells, characterized by a distinct gene expression pattern that is associated with SARS‐CoV‐2 specificity in healthy individuals. Our study underlines the impaired immune system and thus the lower vaccine response rates in ASCT patients. However, since protective vaccine responses and VI CD8+ T‐cells can be induced in part of ASCT patients, our data advocate early posttransplant vaccination due to the high risk of infection in this vulnerable group.

show abstract

Evaluation of immune response to SARS-CoV-2 Omicron sublineages six months after different vaccination regimens in Italy

Trombetta,

Marchi,

Leonardi

et al. 2023

Acta Tropica

View full text Add to dashboard Cite

Heterologous ChAdOx1-BNT162b2 vaccination in Korean cohort induces robust immune and antibody responses that includes Omicron

Cited by 24 publications

References 47 publications

Comprehensive analysis of immune responses in CLL patients after heterologous COVID-19 vaccination

Comprehensive analysis of immune responses in CLL patients after heterologous COVID-19 vaccination

Comparable CD8⁺ T‐cell responses to SARS‐CoV‐2 vaccination in single‐cell transcriptomics of recently allogeneic transplanted patients and healthy individuals

Evaluation of immune response to SARS-CoV-2 Omicron sublineages six months after different vaccination regimens in Italy

Contact Info

Product

Resources

About

Heterologous ChAdOx1-BNT162b2 vaccination in Korean cohort induces robust immune and antibody responses that includes Omicron

Cited by 24 publications

References 47 publications

Comprehensive analysis of immune responses in CLL patients after heterologous COVID-19 vaccination

Comprehensive analysis of immune responses in CLL patients after heterologous COVID-19 vaccination

Comparable CD8+ T‐cell responses to SARS‐CoV‐2 vaccination in single‐cell transcriptomics of recently allogeneic transplanted patients and healthy individuals

Evaluation of immune response to SARS-CoV-2 Omicron sublineages six months after different vaccination regimens in Italy

Contact Info

Product

Resources

About

Comparable CD8⁺ T‐cell responses to SARS‐CoV‐2 vaccination in single‐cell transcriptomics of recently allogeneic transplanted patients and healthy individuals